Komori
TAUNS Laboratories (197A) · PolicyFirst stated

Delivering High-Quality Products Worldwide in the Infectious Disease POCT Field

First written in FY2024. . Latest entry: FY2024.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Development of the infectious disease POCT and OTC testing businessA theme 2 companies write about · 0 as a headwind · 3 as a tailwind

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2024First statedAnnual report

    「Under the corporate slogan “Safe days, through diagnostic technology,” we have developed and sold many products in the infectious disease POCT field for more than 30 years since our founding, with the aim of providing high-quality products worldwide and creating safe days for people around the world.」

    The company describes providing high-quality products in Japan and overseas, centered on point-of-care testing for infectious diseases in clinical settings.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for TAUNS Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Delivering High-Quality Products Worldwide in the Infectious Disease POCT Field | TAUNS Laboratories,Inc. (197A) | Komori